Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Additionally we are shipping Sclerostin Antibodies (93) and Sclerostin Proteins (12) and many more products for this protein.
Showing 10 out of 52 products:
Human Sclerostin ELISA Kit for Sandwich ELISA - ABIN415155
Brabnikova Maresova, Pavelka, Stepan: Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes. in Calcified tissue international 2013
Show all 3 references for ABIN415155
Rat (Rattus) Sclerostin ELISA Kit for Sandwich ELISA - ABIN416496
Kim, Lee, Jo, Song, Lim, Park, Bonewald, Kim: Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes. in Life sciences 2013
Show all 2 references for ABIN416496
Mouse (Murine) Sclerostin ELISA Kit for Sandwich ELISA - ABIN1889353
Brunkow, Gardner, Van Ness, Paeper, Kovacevich, Proll, Skonier, Zhao, Sabo, Fu, Alisch, Gillett, Colbert, Tacconi, Galas, Hamersma, Beighton, Mulligan: Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. in American journal of human genetics 2001
Show all 2 references for ABIN1889353
The aims of this study were to evaluate OCN and sclerostin levels in subjects who underwent coronary artery bypass graft (CABG) surgery compared with those in normal controls.
two affected siblings who carried a novel nonsense mutation of SOST in a consanguineous family from China, is reported.
Sclerostin serum levels are not associated with an adverse metabolic profile during pregnancy in women with GDM and PE
Quantitative RT-PCR analysis showed that SOST expression dose-dependently decreased with increasing Wnt (show WNT2 ELISA Kits) signaling, while BMP4 (show BMP4 ELISA Kits) induced SOST expression
SOST and DKK1 (show DKK1 ELISA Kits) have opposing effects on PC3 (show PCSK1 ELISA Kits) cell invasion and bone-derived Wnt (show WNT2 ELISA Kits) signaling positively contributes to the invasive phenotypes of PC3 (show PCSK1 ELISA Kits)
The correlation of SOST polymorphisms with changes of BMD (show BEST1 ELISA Kits) and bone biomarkers after treatment was analyzed.
highly sulfated (show SULF1 ELISA Kits) glycosaminoglycans might control bone homeostasis via interference with sclerostin/LRP5 (show LRP5 ELISA Kits)/6 complex formation.
Serum sclerostin was associated with serum intact parathyroid hormone (show PTH ELISA Kits) in patients undergoing peritoneal dialysis.
Sclerostin and DKK-1 (show DKK1 ELISA Kits) concentrations were markedly lower in HIV-infected youths
Serum sclerostin levels inversely associated with vascular calcification burden and progression in prevalent renal transplant recipients
Our results suggested that sclerostin could be expressed in the liver and sustained successfully at high levels in the blood by using the PhiC31 integrase system, leading to trabecular bone loss.
Sclerostin depletion enhances tibial fracture healing.
SOST gene is involved in the regulation of renal interstitial fibrosis (RIF) progression. In obstructive kidney injury, SOST gene deletion would probably enhance renal fibrogenic response and promote the progression of RIF.
Data (including data from studies in knockout/transgenic mice) suggest that Lrp6 (lipoprotein receptor-related protein 6 (show LRP6 ELISA Kits)) is required for suppression of Sost expression by parathyroid hormone (show PTH ELISA Kits) (here, human PTH (show PTH ELISA Kits) peptide 1-34).
These in vivo data support in vitro studies regarding the mechanism of HBM (show LRP5 ELISA Kits)-causing mutations, and imply that HBM LRP5 (show LRP5 ELISA Kits) receptors differ in their relative sensitivity to inhibition by SOST and DKK1 (show DKK1 ELISA Kits).
These findings indicated that AMPK (show PRKAA1 ELISA Kits) regulated RANKL (show TNFSF11 ELISA Kits) and sclerostin expression through the mevalonate pathway in osteocytes.
Sclerostin inhibits bone formation through Lrp5 (show LRP5 ELISA Kits) interaction.
thyroid hormone (show PTH ELISA Kits)-induced changes in bone remodeling are associated with a divergent regulation of DKK1 (show DKK1 ELISA Kits) and sclerostin
increased sclerostin production achieved by HDAC5 (show HDAC5 ELISA Kits) shRNA is abrogated by simultaneous knockdown of MEF2C (show MEF2C ELISA Kits), indicating that MEF2C (show MEF2C ELISA Kits) is a major target of HDAC5 (show HDAC5 ELISA Kits) in osteocytes
sclerostin is regulated by glutathione, N-acetylcysteine and lipoic acid in osteocytes in a process involving JNK (show MAPK8 ELISA Kits) and ERK1/2 (show MAPK1/3 ELISA Kits)
Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease.